PofoliaShared via Pofolia

American Journal of Respiratory and Critical Care Medicine· 2022Q1· Guideline

Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

Ganesh Raghu, Martine Remy-Jardin, Luca Richeldi, Carey C. Thomson et al.

Short summary

New guidelines conditionally recommend transbronchial lung cryobiopsy as an alternative to surgical biopsy for IPF and suggest nintedanib for progressive pulmonary fibrosis (PPF) in non-IPF ILDs.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Transbronchial lung cryobiopsy is conditionally recommended as an alternative to surgical lung biopsy for IPF in expert centers.
  • Antacid medication and antireflux surgery are conditionally recommended against for IPF treatment.
  • Progressive pulmonary fibrosis (PPF) is defined by specific worsening criteria in non-IPF ILDs.
  • Nintedanib is conditionally recommended for PPF, while pirfenidone requires additional research.

AI-generated from the title and abstract; the full text is not read.

Abstract

Abstract Background This American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Asociación Latinoamericana de Tórax guideline updates prior idiopathic pulmonary fibrosis (IPF) guidelines and addresses the progression of pulmonary fibrosis in patients with interstitial lung diseases (ILDs) other than IPF. Methods A committee was composed of multidisciplinary experts in ILD, methodologists, and patient representatives. 1) Update of IPF: Radiological and histopathological criteria for IPF were updated by consensus. Questions about transbronchial lung cryobiopsy, genomic classifier testing, antacid medication, and antireflux surgery were informed by systematic reviews and answered with evidence-based recommendations using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. 2) Progressive pulmonary fibrosis (PPF): PPF was defined, and then radiological and physiological criteria for PPF were determined by consensus. Questions about pirfenidone and nintedanib were informed by systematic reviews and answered with evidence-based recommendations using the GRADE approach. Results 1) Update of IPF: A conditional recommendation was made to regard transbronchial lung cryobiopsy as an acceptable alternative to surgical lung biopsy in centers with appropriate expertise. No recommendation was made for or against genomic classifier testing. Conditional recommendations were made against antacid medication and antireflux surgery for the treatment of IPF. 2) PPF: PPF was defined as at least two of three criteria (worsening symptoms, radiological progression, and physiological progression) occurring within the past year with no alternative explanation in a patient with an ILD other than IPF. A conditional recommendation was made for nintedanib, and additional research into pirfenidone was recommended. Conclusions The conditional recommendations in this guideline are intended to provide the basis for rational, informed decisions by clinicians.

The authors' abstract, as published at the source. American Journal of Respiratory and Critical Care Medicine, 2022 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Pulmonary and Respiratory Medicine

Pulmonary and Respiratory MedicineMedicine